The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: FBXL16 (UniProt Q8N461; Homo sapiens)

0) Target verification (critical identity checks)

The literature summarized here is restricted to human FBXL16, an F-box/LRR-repeat protein matching UniProt Q8N461 (also referenced as Q8N461/AlphaFold in the AD study), and not other similarly named F-box genes (e.g., FBXL6, FBXO16). Across the retrieved primary studies, the protein is consistently described as an F-box protein with a C-terminal leucine-rich repeat (LRR) region and implicated in ubiquitin–proteasome regulation, aligning with the UniProt description provided. (qu2024fbxl16anew pages 1-2, qu2024fbxl16anew pages 7-9)

1) Key concepts and definitions (current understanding)

1.1 What FBXL16 is (molecular class)

FBXL16 is generally described as an F-box E3 ubiquitin ligase component (or E3 regulator) bearing: (i) an F-box motif (classically mediating interaction with SKP1 in SCF complexes), and (ii) a C-terminal LRR domain used for substrate recognition; one report also describes an N-terminal proline-rich region. (qu2024fbxl16anew pages 1-2, shah2022fbxl16promotesbreast pages 110-114)

1.2 Canonical expectation vs. emerging non-canonical behavior

In canonical SCF (SKP1–CUL1–F-box) E3 ligases, the F-box protein recruits substrate while the CUL1/RBX1 module supports ubiquitin transfer. However, breast cancer-focused mechanistic work reports that FBXL16 can associate with SKP1 yet shows no detectable interaction with CUL1, implying non-canonical behavior for an F-box protein and leaving the precise E3 architecture context-dependent or unresolved. (shah2022fbxl16promotesbreast pages 110-114, shah2022fbxl16promotesbreast pages 31-36)

1.3 Core functional theme from recent studies: bidirectional control of protein stability

Recent literature converges on FBXL16 as a regulator of protein stability with at least two modes:
- Promoting ubiquitination and proteasomal degradation of certain proteins (e.g., APP in AD models). (qu2024fbxl16anew pages 11-16, qu2024fbxl16anew media 3bf912ae)
- Stabilizing certain signaling proteins by increasing their half-life or decreasing their ubiquitination (e.g., IRS1 in KRAS-mutant LUAD; ERα in ER+ breast cancer). (morel2024fbxl16promotescell pages 7-9, morel2024fbxl16promotescell pages 10-11, shah2022fbxl16promotesbreast pages 7-10)

2) Recent developments and latest research (prioritizing 2023–2024)

2.1 2024—Alzheimer’s disease: FBXL16 drives ubiquitination-dependent APP degradation and improves cognition

Study: Qu et al., Biomarker Research (published Nov 2024). URL: https://doi.org/10.1186/s40364-024-00691-w (qu2024fbxl16anew pages 1-2)

Key claims supported by experimental evidence:
1. FBXL16 promotes ubiquitination-dependent proteasomal degradation of APP. Evidence includes co-immunoprecipitation and proteasome inhibition (MG132), cycloheximide (CHX) experiments, and direct ubiquitination readouts. (qu2024fbxl16anew pages 1-2, qu2024fbxl16anew pages 7-9, qu2024fbxl16anew media 3bf912ae)
2. Cytoplasmic co-localization and binding: FBXL16 and APP co-localize in the cytoplasm in neuronal cell models and co-immunoprecipitate (Flag-FBXL16 with Myc-APP). (qu2024fbxl16anew pages 7-9)
3. In vivo functional outcomes: Lentiviral hippocampal FBXL16 overexpression in 3×Tg AD mice is reported to increase ubiquitination, decrease APP, reduce neuroinflammation markers, and improve cognition in Morris water maze and Y-maze assays; conditional FBXL16 knockout worsens behavioral performance and increases APP levels. (qu2024fbxl16anew pages 11-16, qu2024fbxl16anew media 3bf912ae)

Network/interactome insight: Overexpression + Flag-IP LC–MS/MS identified 141 interacting proteins, enriched for ubiquitin-dependent catabolic processes (reported enrichment p = 1.04E−09) and with links to cognition/aging traits in GAD analysis (reported p-values on the order of ~10−6). (qu2024fbxl16anew pages 7-9)

Regulatory note: The same work maps a core promoter region and reports transcriptional activation by E2F1 via promoter assays. (qu2024fbxl16anew pages 7-9, qu2024fbxl16anew pages 11-16)

2.2 2024—KRAS-mutant lung adenocarcinoma: FBXL16 stabilizes IRS1 and promotes AKT signaling and drug resistance

Study: Morel & Long, Molecular Oncology (published Jan 2024). URL: https://doi.org/10.1002/1878-0261.13554 (morel2024fbxl16promotescell pages 7-9)

Key mechanistic findings:
1. FBXL16 stabilizes IRS1 protein, thereby enhancing IGF1/IRS1/AKT signaling outputs (pAKT, pS6K/pS6) and supporting growth/migration. (morel2024fbxl16promotescell pages 11-13, morel2024fbxl16promotescell pages 10-11)
2. Protein half-life effect (CHX chase):
- In A549 cells, IRS1 half-life shifts from ~5.5 h (control) to ~0.9 h (FBXL16 knockdown).
- In NL-20 cells, IRS1 half-life shifts from ~1.8 h (control) to ~8 h (FBXL16 overexpression) (n = 3). (morel2024fbxl16promotescell pages 10-11)
3. Domain requirement: IRS1 interaction requires the LRR domain, and both F-box and LRR domains are necessary for IRS1 stabilization/signaling effects. (morel2024fbxl16promotescell pages 11-13)

Quantitative clinical/statistical evidence:
- FBXL16–IRS1 correlation: cell lines Pearson r = 0.93, R² = 0.86, P < 0.001; patient samples N = 102, r = 0.6, R² = 0.36, P < 0.001. (morel2024fbxl16promotescell pages 7-9)
- CPTAC comparison indicates IRS1 is upregulated in KRAS-mutant LUAD (KRAS WT N = 77 vs mutant N = 33). (morel2024fbxl16promotescell pages 7-9)

Therapeutic relevance: FBXL16 depletion increases sensitivity to the KRASG12C inhibitor sotorasib in resistant LUAD cells, consistent with reduced AKT pathway signaling upon combined treatment. (morel2024fbxl16promotescell pages 7-9)

Visual corroboration: The retrieved figure panels include expression/prognosis comparisons, IRS1 correlation, CHX stability assays, and AKT pathway signaling outputs. (morel2024fbxl16promotescell media f8a89b7d)

2.3 2024—COPD fibroblast biology: miR-1307-5p directly targets FBXL16 and promotes myofibroblast transdifferentiation

Study: Yao et al., Respiratory Research (published Oct 2024). URL: https://doi.org/10.1186/s12931-024-03007-6 (yao2024mir13075penhancesfibroblast pages 5-6)

Key findings:
- miR-1307-5p is increased in COPD blood and lung tissues (reported n = 6 per group) and in primary fibroblasts from COPD patients; TGF-β induces miR-1307-5p in MRC-5 fibroblasts and miR-1307-5p enhances fibroblast activation/transdifferentiation marker expression. (yao2024mir13075penhancesfibroblast pages 5-6)
- FBXL16 is a direct miR-1307-5p target: in silico prediction finds two seed matches in the FBXL16 3′UTR; miR-1307-5p suppresses FBXL16 mRNA and represses WT (but not mutant) FBXL16 3′UTR luciferase reporters, supporting direct targeting. (yao2024mir13075penhancesfibroblast pages 5-6)
- In smoke-exposed mice, miR-1307-5p overexpression worsens inflammatory cell infiltration and lung pathology/dysfunction. (yao2024mir13075penhancesfibroblast pages 5-6)

Interpretation: In this COPD model, FBXL16 is positioned functionally as part of an FBXL16/HIF1α axis (per study framing), with strong evidence for upstream miRNA repression of FBXL16 and downstream fibroblast activation phenotypes. (yao2024mir13075penhancesfibroblast pages 5-6)

3) Current applications and real-world implementations

3.1 Oncology: biomarker and combination-therapy target in KRAS-mutant LUAD

The LUAD study explicitly argues that FBXL16 may be a therapeutic target in KRAS-mutant lung adenocarcinoma, motivated by (i) selective upregulation in KRAS-mutant disease, (ii) functional dependence of growth/migration on FBXL16, and (iii) enhanced response to sotorasib when FBXL16 is depleted, consistent with overcoming PI3K/AKT-mediated resistance. (morel2024fbxl16promotescell pages 7-9, morel2024fbxl16promotescell media f8a89b7d)

Real-world implementation angle: These findings support FBXL16 as a candidate node for combination strategies (KRASG12C inhibitor + FBXL16 pathway blockade), and as a potential biomarker aligned with IRS1/AKT pathway activation (noting strong FBXL16–IRS1 correlation in patient samples). (morel2024fbxl16promotescell pages 7-9)

3.2 Neurodegeneration: UPS activation strategy focused on APP burden

In AD models, FBXL16 overexpression is used as a functional intervention (lentiviral hippocampal overexpression) that reduces APP and neuroinflammation with improved cognitive outcomes, positioning FBXL16 as a potential upstream lever in “activate UPS to dismantle disease-related proteins” strategies. (qu2024fbxl16anew pages 1-2, qu2024fbxl16anew pages 11-16, qu2024fbxl16anew media 3bf912ae)

3.3 Pulmonary disease: miRNA–FBXL16 axis as a mechanistic and therapeutic handle

The COPD study supports a plausible translational path in which modulation of miR-1307-5p (or protecting FBXL16 from miRNA repression) could alter fibroblast activation programs relevant to airway remodeling. (yao2024mir13075penhancesfibroblast pages 5-6)

4) Expert opinions and analysis (authoritative interpretations in retrieved sources)

4.1 FBXL16 appears context-dependent: degrader in one system, stabilizer in another

A key synthesis across studies is that FBXL16 does not behave as a simple “always-degrade” substrate receptor. Instead:
- In AD models, FBXL16 promotes ubiquitination and proteasomal degradation of APP. (qu2024fbxl16anew pages 11-16, qu2024fbxl16anew media 3bf912ae)
- In KRAS-mutant LUAD, FBXL16 increases IRS1 stability (increasing half-life and sustaining signaling), which is functionally pro-oncogenic and pro-resistance. (morel2024fbxl16promotescell pages 7-9, morel2024fbxl16promotescell pages 10-11)
- In ER+ breast cancer, FBXL16 is presented as a positive regulator of ERα stability and endocrine resistance (via reduced ubiquitination), and also reported to stabilize oncoproteins such as c-MYC and β-catenin in related contexts. (shah2022fbxl16promotesbreast pages 7-10, shah2022fbxl16promotesbreast pages 31-36)

A coherent mechanistic hypothesis (supported indirectly by the above) is that FBXL16 may act either as (i) a substrate receptor that promotes ubiquitination and degradation for some targets, or (ii) a competitor/antagonist/modulator of other ubiquitin ligases for other targets, thereby stabilizing them. The breast cancer work explicitly highlights uncertainty around canonical SCF assembly due to lack of detectable CUL1 interaction, reinforcing that FBXL16’s E3 context may be non-canonical. (shah2022fbxl16promotesbreast pages 110-114, shah2022fbxl16promotesbreast pages 31-36)

4.2 Subcellular localization and where FBXL16 acts

Direct localization evidence in the retrieved set includes cytoplasmic co-localization of FBXL16 with APP in neuronal cell models, consistent with cytoplasmic engagement of APP for ubiquitination and turnover. (qu2024fbxl16anew pages 7-9)

5) Relevant statistics and data highlights (from recent studies)

5.1 LUAD (Morel & Long 2024)

• FBXL16–IRS1 protein correlation: cell lines r = 0.93 (R² = 0.86, P < 0.001); patients N = 102 r = 0.6 (R² = 0.36, P < 0.001). (morel2024fbxl16promotescell pages 7-9)
• IRS1 half-life shifts with FBXL16 perturbation: 5.5 h → 0.9 h (A549; knockdown) and 1.8 h → 8 h (NL-20; overexpression), n = 3. (morel2024fbxl16promotescell pages 10-11)
• Visual panels substantiate expression/prognosis and pathway readouts. (morel2024fbxl16promotescell media f8a89b7d)

5.2 AD (Qu et al. 2024)

• Proteomics: 141 FBXL16-associated proteins identified; GO enrichment for ubiquitin-dependent protein catabolic process reported at p = 1.04E−09; cognition/aging trait enrichment at ~10−6 in GAD analysis. (qu2024fbxl16anew pages 7-9)
• In vivo: behavioral improvements and biochemical changes are reported as significant (P<0.05; P<0.01) under FBXL16 overexpression relative to controls; conditional knockout worsens behavioral performance and increases APP. (qu2024fbxl16anew pages 11-16, qu2024fbxl16anew media 3bf912ae)

5.3 COPD (Yao et al. 2024)

• Human sample size for miR-1307-5p elevation: n = 6/group (blood/lung tissues). (yao2024mir13075penhancesfibroblast pages 5-6)
• Direct targeting: WT vs mutant 3′UTR luciferase supports miR-1307-5p → FBXL16 regulation; statistical framework uses t-test/ANOVA with p < 0.05 / p < 0.01 thresholds. (yao2024mir13075penhancesfibroblast pages 5-6)

Summary of experimentally supported functional annotation

FBXL16 (Q8N461) is best annotated, based on the recent experimental literature retrieved here, as a protein-stability regulator linked to the ubiquitin–proteasome system, with evidence for both:
- E3-like substrate degradation (APP degradation in Alzheimer’s models), and
- stabilization of signaling regulators (IRS1 in KRAS-mutant LUAD; ERα in ER+ breast cancer),
with functional consequences across neurodegeneration, cancer growth/drug resistance, and fibroblast activation in COPD. (qu2024fbxl16anew pages 11-16, morel2024fbxl16promotescell pages 7-9, shah2022fbxl16promotesbreast pages 7-10, yao2024mir13075penhancesfibroblast pages 5-6)

Evidence table

The following table consolidates substrates, contexts, evidence types, and quantitative highlights.

Table: This table summarizes experimentally supported FBXL16 actions, targets, and methods across the studies retrieved in this chat. It highlights where evidence is strongest for substrate degradation or stabilization, and where conclusions remain more indirect.

References

1. (qu2024fbxl16anew pages 1-2): Liqun Qu, Yong Tang, Jianhui Wu, Xiaoyun Yun, Hang Hong Lo, Linlin Song, Xingxia Wang, Huimiao Wang, Ruilong Zhang, Menghan Liu, Cairen Wang, Jerome P. L. Ng, Xianjun Fu, Io Nam Wong, Vincent Kam Wai Wong, and Betty Yuen Kwan Law. Fbxl16: a new regulator of neuroinflammation and cognition in alzheimer’s disease through the ubiquitination-dependent degradation of amyloid precursor protein. Biomarker Research, Nov 2024. URL: https://doi.org/10.1186/s40364-024-00691-w, doi:10.1186/s40364-024-00691-w. This article has 14 citations and is from a peer-reviewed journal.

2. (qu2024fbxl16anew pages 7-9): Liqun Qu, Yong Tang, Jianhui Wu, Xiaoyun Yun, Hang Hong Lo, Linlin Song, Xingxia Wang, Huimiao Wang, Ruilong Zhang, Menghan Liu, Cairen Wang, Jerome P. L. Ng, Xianjun Fu, Io Nam Wong, Vincent Kam Wai Wong, and Betty Yuen Kwan Law. Fbxl16: a new regulator of neuroinflammation and cognition in alzheimer’s disease through the ubiquitination-dependent degradation of amyloid precursor protein. Biomarker Research, Nov 2024. URL: https://doi.org/10.1186/s40364-024-00691-w, doi:10.1186/s40364-024-00691-w. This article has 14 citations and is from a peer-reviewed journal.

3. (shah2022fbxl16promotesbreast pages 110-114): KN Shah. Fbxl16 promotes breast cancer cell growth and diminishes fulvestrant responsiveness by stabilizing erα protein. Unknown journal, 2022.

4. (shah2022fbxl16promotesbreast pages 31-36): KN Shah. Fbxl16 promotes breast cancer cell growth and diminishes fulvestrant responsiveness by stabilizing erα protein. Unknown journal, 2022.

5. (qu2024fbxl16anew pages 11-16): Liqun Qu, Yong Tang, Jianhui Wu, Xiaoyun Yun, Hang Hong Lo, Linlin Song, Xingxia Wang, Huimiao Wang, Ruilong Zhang, Menghan Liu, Cairen Wang, Jerome P. L. Ng, Xianjun Fu, Io Nam Wong, Vincent Kam Wai Wong, and Betty Yuen Kwan Law. Fbxl16: a new regulator of neuroinflammation and cognition in alzheimer’s disease through the ubiquitination-dependent degradation of amyloid precursor protein. Biomarker Research, Nov 2024. URL: https://doi.org/10.1186/s40364-024-00691-w, doi:10.1186/s40364-024-00691-w. This article has 14 citations and is from a peer-reviewed journal.

6. (qu2024fbxl16anew media 3bf912ae): Liqun Qu, Yong Tang, Jianhui Wu, Xiaoyun Yun, Hang Hong Lo, Linlin Song, Xingxia Wang, Huimiao Wang, Ruilong Zhang, Menghan Liu, Cairen Wang, Jerome P. L. Ng, Xianjun Fu, Io Nam Wong, Vincent Kam Wai Wong, and Betty Yuen Kwan Law. Fbxl16: a new regulator of neuroinflammation and cognition in alzheimer’s disease through the ubiquitination-dependent degradation of amyloid precursor protein. Biomarker Research, Nov 2024. URL: https://doi.org/10.1186/s40364-024-00691-w, doi:10.1186/s40364-024-00691-w. This article has 14 citations and is from a peer-reviewed journal.

7. (morel2024fbxl16promotescell pages 7-9): Marion Morel and Weiwen Long. fbxl16 promotes cell growth and drug resistance in lung adenocarcinomas with kras mutation by stabilizing irs1 and upregulating irs1/akt signaling. Molecular Oncology, 18:762-777, Jan 2024. URL: https://doi.org/10.1002/1878-0261.13554, doi:10.1002/1878-0261.13554. This article has 11 citations and is from a peer-reviewed journal.

8. (morel2024fbxl16promotescell pages 10-11): Marion Morel and Weiwen Long. fbxl16 promotes cell growth and drug resistance in lung adenocarcinomas with kras mutation by stabilizing irs1 and upregulating irs1/akt signaling. Molecular Oncology, 18:762-777, Jan 2024. URL: https://doi.org/10.1002/1878-0261.13554, doi:10.1002/1878-0261.13554. This article has 11 citations and is from a peer-reviewed journal.

9. (shah2022fbxl16promotesbreast pages 7-10): KN Shah. Fbxl16 promotes breast cancer cell growth and diminishes fulvestrant responsiveness by stabilizing erα protein. Unknown journal, 2022.

10. (morel2024fbxl16promotescell pages 11-13): Marion Morel and Weiwen Long. fbxl16 promotes cell growth and drug resistance in lung adenocarcinomas with kras mutation by stabilizing irs1 and upregulating irs1/akt signaling. Molecular Oncology, 18:762-777, Jan 2024. URL: https://doi.org/10.1002/1878-0261.13554, doi:10.1002/1878-0261.13554. This article has 11 citations and is from a peer-reviewed journal.

11. (morel2024fbxl16promotescell media f8a89b7d): Marion Morel and Weiwen Long. fbxl16 promotes cell growth and drug resistance in lung adenocarcinomas with kras mutation by stabilizing irs1 and upregulating irs1/akt signaling. Molecular Oncology, 18:762-777, Jan 2024. URL: https://doi.org/10.1002/1878-0261.13554, doi:10.1002/1878-0261.13554. This article has 11 citations and is from a peer-reviewed journal.

12. (yao2024mir13075penhancesfibroblast pages 5-6): Li-peng Yao, Zheng-kai Wang, Xin-qing Jiang, Beier Jiang, Si-jia Chen, Zhi-dan Hua, Dan-dan Gao, Quan Zheng, Sheng-mei Zhu, Mao-xiang Qian, Feng Zhang, Li-feng Xu, Cheng-shui Chen, and Fang Lu. Mir-1307-5p enhances fibroblast transdifferentiation to exacerbate chronic obstructive pulmonary disease through regulating fbxl16/hif1α axis. Respiratory Research, Oct 2024. URL: https://doi.org/10.1186/s12931-024-03007-6, doi:10.1186/s12931-024-03007-6. This article has 5 citations and is from a domain leading peer-reviewed journal.

13. (qu2024fbxl16anew pages 2-4): Liqun Qu, Yong Tang, Jianhui Wu, Xiaoyun Yun, Hang Hong Lo, Linlin Song, Xingxia Wang, Huimiao Wang, Ruilong Zhang, Menghan Liu, Cairen Wang, Jerome P. L. Ng, Xianjun Fu, Io Nam Wong, Vincent Kam Wai Wong, and Betty Yuen Kwan Law. Fbxl16: a new regulator of neuroinflammation and cognition in alzheimer’s disease through the ubiquitination-dependent degradation of amyloid precursor protein. Biomarker Research, Nov 2024. URL: https://doi.org/10.1186/s40364-024-00691-w, doi:10.1186/s40364-024-00691-w. This article has 14 citations and is from a peer-reviewed journal.

14. (shah2022fbxl16promotesbreast pages 1-7): KN Shah. Fbxl16 promotes breast cancer cell growth and diminishes fulvestrant responsiveness by stabilizing erα protein. Unknown journal, 2022.

15. (shah2022fbxl16promotesbreast pages 36-43): KN Shah. Fbxl16 promotes breast cancer cell growth and diminishes fulvestrant responsiveness by stabilizing erα protein. Unknown journal, 2022.

Artifacts

• Edison artifact artifact-00
  
  

Citations

1. https://doi.org/10.1186/s40364-024-00691-w
2. https://doi.org/10.1002/1878-0261.13554
3. https://doi.org/10.1186/s12931-024-03007-6
4. https://doi.org/10.1186/s40364-024-00691-w,
5. https://doi.org/10.1002/1878-0261.13554,
6. https://doi.org/10.1186/s12931-024-03007-6,

FBXL16 Client Stabilization Mechanism: Anti-Degradative Adaptor or Context-Dependent Dual-Function F-Box Protein?

Summary

FBXL16 (F-box and leucine-rich repeat protein 16, UniProt Q8N461) is a structurally atypical member of the F-box protein family that stabilizes multiple oncoproteins — most notably c-MYC, IRS1, SRC-3, and beta-catenin — by functioning as a catalytically dead decoy within the SCF (SKP1–CUL1–F-box) ubiquitin ligase system. The strongest mechanistic evidence, from Morel et al. (2020), demonstrates that FBXL16 binds SKP1 via its N-terminal F-box domain and substrates (e.g., c-MYC) via its C-terminal leucine-rich repeat (LRR) domain, but critically does not interact with the scaffold protein CUL1. This inability to recruit CUL1 renders FBXL16 incapable of assembling a functional E3 ligase complex, and instead it sequesters substrates away from bona fide degradative SCF complexes such as SCF-FBW7 and SCF-beta-TrCP. The result is protein stabilization through competitive antagonism rather than catalytic activity.

However, this elegant decoy model is complicated by two reports showing FBXL16 can promote degradation of specific targets: HIF1alpha in triple-negative breast cancer (PMID: 34818544) and LATS2 in the Hippo signaling pathway (PMID: 38200110). These contradictory findings suggest FBXL16 possesses context-dependent dual functionality — acting as a stabilizer for some substrates and a degrader for others — raising fundamental questions about how a protein that reportedly cannot bind CUL1 can nonetheless mediate ubiquitin-dependent degradation. The resolution of this paradox remains an open question in the field.

Current Gene Ontology (GO) annotations for FBXL16 are misleading: they classify it as a canonical SCF complex component (GO:0019005) involved in SCF-dependent proteasomal degradation (GO:0031146), based on phylogenetic inference (IBA evidence code) rather than direct experimentation. These annotations fail to capture FBXL16's dominant anti-degradative activity and urgently require revision. We propose that a new molecular function term — such as "anti-degradative substrate adaptor activity" — is needed to accurately describe FBXL16's primary mechanism of action. Notably, no published evidence links FBXL16 to ERalpha/ESR1 stabilization.

Key Findings

Finding 1: FBXL16 Stabilizes c-MYC by Antagonizing FBW7-Mediated Ubiquitination (Strongest Evidence)

The most mechanistically detailed study of FBXL16 function was published by Morel, Shah, and Long in 2020 (PMID: 32345600). This work established that FBXL16 directly binds c-MYC through its C-terminal LRR domain and SKP1 through its N-terminal F-box domain. The critical discovery was that FBXL16 does not interact with CUL1, the scaffold protein essential for assembling a functional SCF ubiquitin ligase complex. As the authors stated: "Because it does not interact with the scaffold protein cullin 1 (CUL1), we hypothesized that FBXL16 might not form a functional SCF-E3 ligase complex."

The functional consequence is that FBXL16 competes directly with the tumor suppressor FBW7 (FBXW7) for c-MYC binding. FBW7 is the substrate-recognition component of the SCF-FBW7 complex, which is the principal E3 ligase responsible for c-MYC ubiquitination and proteasomal degradation. By sequestering c-MYC in a catalytically inert FBXL16–SKP1 complex, FBXL16 shields c-MYC from FBW7-mediated ubiquitination. The study demonstrated that FBXL16 "stabilizes C-MYC by antagonizing FBW7-mediated C-MYC ubiquitination and degradation" and that both the F-box domain (for SKP1 binding) and the LRR domain (for substrate binding) are required for this stabilization activity. Furthermore, the paper also reported that "FBXL16 up-regulates the levels of proteins targeted by SCF-E3 ligases, such as C-MYC, beta-catenin, and steroid receptor coactivator 3 (SRC-3)."

This finding is supported by extensive independent literature on FBW7's role as a tumor suppressor that degrades c-MYC (PMID: 33070870; PMID: 37408248). The c-MYC–FBXL16 relationship represents the gold standard for FBXL16 client characterization, with direct binding, domain mapping, ubiquitination assays, and half-life measurements all reported.

{{figure:fbxl16_domain_architecture.png|caption=FBXL16 domain architecture showing F-box domain (SKP1 binding), LRR domain (substrate binding), and the critical absence of CUL1 interaction that defines the anti-degradative decoy mechanism}}

Finding 2: FBXL16 Stabilizes IRS1 in KRAS-Mutant Lung Adenocarcinoma

Morel and Long (2024) extended the FBXL16 story to insulin receptor substrate 1 (IRS1) in the context of KRAS-mutant lung adenocarcinoma (LUAD) (PMID: 37983945). FBXL16 is selectively upregulated in KRAS-mutant tumors and "upregulates insulin receptor substrate 1 (IRS1) protein stability, leading to an increase of IGF1/AKT signaling, thereby promoting cell growth and migration." Importantly, this study also demonstrated therapeutic relevance: "FBXL16 depletion greatly enhances sensitivity to the KRASG12C inhibitor (sotorasib) in resistant cells by downregulating phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB; also known as AKT) signaling."

IRS1 is a known substrate of at least two SCF-type E3 ligases: SCF-beta-TrCP, which targets IRS1 following mTORC1-mediated phosphorylation at Ser422 (PMID: 30240640), and SCF-Fbxo40, which ubiquitinates IRS1 in skeletal muscle downstream of IGF1R activation (PMID: 22033112). The involvement of multiple SCF-type ligases in IRS1 turnover is consistent with FBXL16's proposed decoy mechanism — by sequestering IRS1, FBXL16 could shield it from degradation by any of these competing E3 complexes.

While the IRS1 study did not include the same depth of domain-mapping experiments as the c-MYC work, the consistent involvement of the same research group (Morel and Long) and the coherent mechanistic framework with the c-MYC findings lend strong support to this client relationship.

Finding 3: SRC-3 and Beta-Catenin Stabilization — Confirmed but Mechanistically Shallow

FBXL16 was reported to upregulate the protein levels of both SRC-3 (steroid receptor coactivator 3) and beta-catenin in addition to c-MYC (PMID: 32345600). An independent confirmation of SRC-3 regulation came from Yang and Jing (2021) (PMID: 34333223), who demonstrated that "FBXL16 deficiency was demonstrated to reduce the level of steroid receptor coactivator 3 (SRC-3) in MDA-MB-231 and MCF-7 cells."

Both SRC-3 and beta-catenin are established substrates of SCF-type E3 ligases: SRC-3 is degraded by SCF-FBW7alpha following GSK3-mediated phosphorylation (PMID: 17574025), and beta-catenin is the canonical substrate of SCF-beta-TrCP within the Wnt destruction complex (PMID: 32129710; PMID: 34352208). The fact that FBXL16 stabilizes substrates of both FBW7 and beta-TrCP suggests it may act as a broad-spectrum antagonist of multiple SCF complexes.

However, neither study demonstrated direct binding of FBXL16 to SRC-3 or beta-catenin, nor were domain-dependence or ubiquitination assays performed for these specific substrates. These relationships therefore remain mechanistically plausible but incompletely characterized. SRC-3 is classified as moderate evidence due to two independent reports, while beta-catenin is weak — mentioned only alongside c-MYC and SRC-3 without dedicated investigation.

Finding 4: FBXL16 Promotes HIF1alpha Degradation — A Mechanistic Paradox

In striking contrast to its stabilizing activity, Kim et al. (2021) reported that FBXL16 acts as a degradative E3 ligase for HIF1alpha in triple-negative breast cancer (PMID: 34818544). The study found that "FBXL16 directly binds to HIF1alpha and induces its ubiquitination and degradation, regardless of the tumor microenvironment, resulting in blockade of the HIF1alpha-mediated epithelial-mesenchymal transition (EMT) and angiogenesis features of breast cancer." In this context, FBXL16 functions as a tumor suppressor — the opposite of its oncogenic role in c-MYC stabilization.

This finding creates a fundamental mechanistic paradox. If FBXL16 cannot bind CUL1 (as demonstrated by Morel et al. 2020), how can it mediate canonical ubiquitin-dependent degradation of HIF1alpha? Several possible explanations exist: (1) alternative E3 ligase recruitment through a non-cullin-based mechanism; (2) context-dependent CUL1 binding regulated by post-translational modifications or cell-type-specific cofactors; (3) indirect promotion of HIF1alpha degradation through stabilization of a negative regulator; or (4) technical discrepancies between experimental systems. The HIF1alpha interaction is notable for being the only FBXL16 interaction confirmed by multiple experiments in the UniProt IntAct database (6 experiments).

Finding 5: FBXL16 Also Degrades LATS2 via the Hippo Pathway

A second degradative target was reported in 2024: LATS2, a core kinase of the Hippo tumor suppressor pathway (PMID: 38200110). The study found that "This oncogenic FBXL16 complex blocks LATS2 condensation by binding to the PRM region to promote its degradation." This further supports the notion that FBXL16's degradative activity is not limited to a single substrate but may represent a genuine alternative mode of action. However, neither the HIF1alpha nor the LATS2 study provides a clear mechanistic explanation for how a protein lacking CUL1 binding can drive ubiquitin-dependent degradation.

Finding 6: No Published Evidence for FBXL16–ERalpha Interaction

Despite ERalpha being listed in the research question as a potential FBXL16 client, multiple PubMed searches combining FBXL16 with ERalpha, estrogen receptor, and ESR1 returned zero results. ERalpha is not mentioned in any of the identified FBXL16 publications. While ERalpha stability is regulated by ubiquitin-proteasome pathways, no connection to FBXL16 has been published as of July 2026. This client relationship is entirely speculative and lacks any supporting evidence.

Finding 7: Current GO Annotations Are Misleading and Require Revision

A SPARQL query of UniProt (Q8N461) revealed that FBXL16 carries only three GO annotations: GO:0005829 (cytosol), GO:0019005 (SCF ubiquitin ligase complex), and GO:0031146 (SCF-dependent proteasomal ubiquitin-dependent protein catabolic process). The UniProt function annotation states: "Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex." However, Morel et al. (2020) explicitly demonstrated that "Because it does not interact with the scaffold protein cullin 1 (CUL1), we hypothesized that FBXL16 might not form a functional SCF-E3 ligase complex."

The existing GO annotations are based on IBA (Inferred from Biological Aspect of Ancestor) evidence codes — phylogenetic inference, not experimental evidence on FBXL16 itself. This represents a textbook case where phylogenetic inference fails because FBXL16 has functionally diverged from its paralogs. The UniProt subunit annotation claiming FBXL16 "Interacts with SKP1 and CUL1" directly contradicts experimental data. Strikingly, FBXL16 has no Molecular Function GO annotation at all — only Cellular Component and Biological Process terms.

{{figure:fbxl16_evidence_matrix.png|caption=Comprehensive evidence matrix for all reported FBXL16 client proteins, showing direct binding, ubiquitination changes, domain dependence, competing ligase involvement, and overall evidence strength}}

Mechanistic Model and Interpretation

The Anti-Degradative Decoy Model (Primary Mode)

The best-supported model for FBXL16 function is as a dominant-negative decoy within the SCF ubiquitin ligase system. The mechanism can be summarized as follows:

CANONICAL SCF COMPLEX (e.g., SCF-FBW7):
  SKP1 ── F-box protein (FBW7) ── CUL1 ── RBX1 ── E2~Ub
|                                      |
    Substrate (c-MYC)  <─── Ubiquitination ────┘
|
    Proteasomal Degradation

FBXL16 DECOY COMPLEX:
  SKP1 ── FBXL16 (F-box + LRR)   ✗   CUL1 (NO interaction)
|
    Substrate (c-MYC)  <─── SEQUESTERED, STABILIZED
|
    NO ubiquitination, NO degradation

COMPETITIVE ANTAGONISM:
  SCF-FBW7    + FBXL16  ──compete──>  c-MYC, SRC-3
  SCF-β-TrCP  + FBXL16  ──compete──>  β-catenin, IRS1

FBXL16 retains the ability to bind SKP1 (potentially also sequestering SKP1 from productive SCF complexes) and to recognize substrates via its LRR domain, but its inability to recruit CUL1 means the catalytic ubiquitin-transfer machinery is never assembled. The net effect is substrate stabilization through competitive sequestration.

The Degradative Mode (Secondary, Context-Dependent)

For HIF1alpha and LATS2, FBXL16 reportedly promotes ubiquitination and degradation. The mechanism for this alternative mode remains unresolved, and several non-exclusive hypotheses should be considered:

1. Alternative E3 recruitment: FBXL16 may recruit non-cullin E3 ligases to specific substrates
2. Context-dependent CUL1 binding: Cell-type-specific cofactors or modifications may enable CUL1 interaction
3. Indirect effects: FBXL16 may stabilize a negative regulator of HIF1alpha or LATS2
4. Bridging protein: An unknown adaptor may connect FBXL16 to CUL1 in certain contexts

{{figure:fbxl16_mechanism_model.png|caption=Mechanistic diagram illustrating FBXL16's dual behavior: anti-degradative decoy for c-MYC/IRS1/SRC-3/beta-catenin versus degradative activity for HIF1alpha/LATS2}}

Evolutionary Precedents for Non-SCF F-Box Proteins

Two important yeast precedents support the concept of F-box proteins functioning outside canonical SCF complexes:

• Rcy1p in S. cerevisiae (PMID: 11287615): Forms a Skp1p–Rcy1p complex without Cdc53p (CUL1 ortholog), Hrt1p, or Cdc34p, and functions in SNARE recycling rather than ubiquitin-dependent degradation. This is the closest known mechanistic analogy to FBXL16's decoy behavior.
• Roy1/Ymr258c in S. cerevisiae (PMID: 21389113): A non-SCF F-box protein that binds Skp1 and inhibits the Rab5-like GTPase Ypt52, functioning as a negative regulator of intracellular transport independently of ubiquitination.

These precedents establish that F-box proteins can form SKP1-containing complexes with non-degradative functions, providing evolutionary context for FBXL16's anti-degradative activity.

Client Protein Evidence Summary Table

GO Annotation Assessment

Current Annotations vs. Experimental Evidence

Recommended Changes

No existing GO molecular function term precisely captures FBXL16's mechanism. "Ubiquitin-protein transferase activity" (GO:0004842) implies degradation. "Ubiquitin ligase inhibitor activity" (GO:0150091) captures antagonism but not substrate binding. "Protein binding" (GO:0005515) is too generic. A new term would fill a genuine gap in the ontology. However, the contradictory HIF1alpha/LATS2 degradation reports complicate a purely anti-degradative annotation and suggest that substrate-specific dual annotations may ultimately be needed.

{{figure:fbxl16_go_assessment.png|caption=Evidence strength ranking for FBXL16 client proteins and assessment of current vs. proposed GO molecular function annotations}}

Evidence Base

Core FBXL16 Studies

Supporting Literature on Competing E3 Ligases

Limitations and Knowledge Gaps

Major Unresolved Questions

1. The CUL1 paradox: How can FBXL16 mediate HIF1alpha and LATS2 degradation if it cannot bind CUL1? No study has directly addressed this contradiction. It is possible that CUL1 binding is context-dependent, that alternative cullin family members are involved, or that the degradation is mediated through a non-SCF mechanism.

2. Structural basis unknown: No crystal structure or cryo-EM structure of FBXL16 (alone or in complex) has been reported. The structural basis for its selective failure to bind CUL1 — despite other F-box proteins doing so — is entirely unknown.

3. Incomplete domain mapping: Only the c-MYC interaction has been mapped to specific FBXL16 domains (F-box for SKP1, LRR for c-MYC). For IRS1, SRC-3, beta-catenin, HIF1alpha, and LATS2, domain-dependence has not been systematically tested.

4. Limited cell-type diversity: Most studies use cancer cell lines. Whether FBXL16's stabilization activity operates in normal tissues is unknown.

5. Quantitative competition dynamics: No study has measured binding affinities (Kd values) of FBXL16 vs. FBW7 for c-MYC, making it unclear how efficiently FBXL16 competes under physiological expression levels.

6. Small literature base: FBXL16 is a relatively understudied protein with approximately 7 primary papers. The contradictory degradation reports (HIF1alpha, LATS2) are from different laboratories with potentially different experimental systems and have not been independently replicated.

7. ERalpha: The absence of published evidence does not exclude a possible FBXL16–ERalpha interaction; it simply has not been tested.

Proposed Follow-up Experiments

High Priority

1. Structural characterization of FBXL16–SKP1 complex: Determine the cryo-EM or crystal structure to understand why CUL1 binding is impaired. Compare with canonical F-box protein structures (FBW7, beta-TrCP) bound to SKP1–CUL1.

2. Reconcile the CUL1 binding paradox: Perform co-immunoprecipitation of FBXL16 with CUL1 across multiple cell types (TNBC, LUAD, normal epithelia) and under varied conditions (normoxia vs. hypoxia, +/- neddylation) to determine if CUL1 interaction is context-dependent.

3. In vitro reconstitution: Reconstitute the FBXL16–SKP1–substrate complex from purified components and test whether it can recruit CUL1–RBX1 or alternative cullin complexes.

4. Quantitative binding affinity measurements: Use SPR, ITC, or fluorescence polarization to measure binding affinities of FBXL16 vs. FBW7 for shared substrates (c-MYC, SRC-3), establishing whether competitive sequestration is thermodynamically plausible at physiological concentrations.

Medium Priority

1. Systematic domain mapping for all clients: Test F-box and LRR deletion/mutation constructs for binding to IRS1, SRC-3, beta-catenin, HIF1alpha, and LATS2.

2. Proteome-wide substrate identification: Perform BioID or AP-MS proteomics to identify the complete FBXL16 interactome and discover additional client proteins.

3. Ubiquitome analysis: Compare global ubiquitination profiles (K-epsilon-GG proteomics) in FBXL16-overexpressing vs. FBXL16-knockout cells.

Lower Priority

1. GO annotation correction: Submit evidence-based requests to the Gene Ontology Consortium and UniProt to correct FBXL16 annotations.

2. ERalpha testing: Directly test whether FBXL16 affects ERalpha protein levels in breast cancer cells.

3. In vivo validation: Generate conditional FBXL16 knockout mice to assess physiological consequences on c-MYC, IRS1, and HIF1alpha levels.

Conclusion

FBXL16 represents a remarkable example of evolutionary repurposing within the F-box protein family. Its primary, best-supported function is as an anti-degradative substrate adaptor — a catalytically dead decoy that sequesters SCF substrates from productive ubiquitin ligase complexes. The c-MYC–FBW7 antagonism is the most rigorously characterized mechanism (Tier 1 evidence), with IRS1 stabilization providing therapeutically relevant confirmation (Tier 2). SRC-3 and beta-catenin stabilization are supported but mechanistically shallow (Tiers 3–4). The contradictory reports of HIF1alpha and LATS2 degradation reveal either genuine dual functionality or unresolved technical discrepancies requiring urgent investigation.

Current GO and UniProt annotations are experimentally inaccurate, based on phylogenetic inference that incorrectly classifies FBXL16 as a canonical SCF component. A refined annotation framework — including a new molecular function term such as "anti-degradative substrate adaptor activity" — is needed to accurately represent FBXL16's dominant mechanism. ERalpha has no published connection to FBXL16, and this putative client relationship lacks any supporting evidence.

OpenScientist prompt: FBXL16 client stabilization mechanism

Investigate how human FBXL16 stabilizes reported client proteins and whether this reflects direct anti-degradative substrate-adaptor behavior, competition with other E3 ligases, inhibition of ubiquitination, or indirect signaling.

Focus on clients reported in the literature, including IRS1, ERalpha, c-MYC, SRC-3, beta-catenin, or other named proteins. For each client, evaluate:

• direct FBXL16 binding;
• ubiquitination changes and protein half-life effects;
• dependence on the FBXL16 F-box and LRR domains;
• competing ligase involvement and whether the effect is degradative or stabilizing.

Please assess whether existing GO-style molecular-function terms capture FBXL16 adequately or whether a new/refined anti-degradative adaptor concept is needed. Include PMIDs and note which client relationships are strongest versus speculative.